Elanco Animal Health Incorporated Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Elanco Animal Health Incorporated (ELAN) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $14.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $14.00M, a 96.42% decline year-over-year.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$92.00M, a 148.94% decline year-over-year.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $58.00M.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$7.00M, a 103.45% decline year-over-year.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $630.00M.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$505.00M, a 500.79% decline from fiscal 2023.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $126.00M.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$183.00M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.00M 10-Q · filed 2026-08-05 | -$78.00M 10-Q · filed 2026-08-05 | -$20.00M derived: sum of 3 quarters · filed 2026-08-05 | -$27.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$92.00M 10-Q · filed 2026-08-05 | -$34.00M derived: sum of 2 quarters · filed 2026-08-05 | -$41.00M derived: sum of 3 quarters · filed 2026-08-05 | $350.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $58.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $51.00M derived: sum of 2 quarters · filed 2026-02-24 | $442.00M derived: sum of 3 quarters · filed 2026-08-05 | $630.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$7.00M 10-Q · filed 2025-11-05 | $384.00M derived: sum of 2 quarters · filed 2026-08-05 | $572.00M 10-Q · filed 2025-11-05 | $140.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $391.00M 10-Q · filed 2026-08-05 | $579.00M 10-Q · filed 2026-08-05 | $147.00M derived: sum of 3 quarters · filed 2026-08-05 | $350.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $188.00M 10-Q · filed 2026-08-05 | -$244.00M derived: sum of 2 quarters · filed 2026-08-05 | -$41.00M derived: sum of 3 quarters · filed 2026-08-05 | -$118.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2024-12-31 | -$432.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$229.00M derived: sum of 2 quarters · filed 2026-02-24 | -$306.00M derived: sum of 3 quarters · filed 2026-02-24 | -$505.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $203.00M 10-Q · filed 2025-11-05 | $126.00M derived: sum of 2 quarters · filed 2025-11-05 | -$73.00M 10-Q · filed 2025-11-05 | $143.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$77.00M 10-Q · filed 2025-11-05 | -$276.00M 10-Q · filed 2025-08-07 | -$60.00M derived: sum of 3 quarters · filed 2026-02-24 | -$261.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$199.00M 10-Q · filed 2025-11-05 | $17.00M derived: sum of 2 quarters · filed 2026-02-24 | -$184.00M derived: sum of 3 quarters · filed 2026-02-24 | -$155.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $216.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $15.00M derived: sum of 2 quarters · filed 2026-02-24 | $44.00M derived: sum of 3 quarters · filed 2026-02-24 | $126.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$201.00M 10-Q · filed 2024-11-07 | -$172.00M derived: sum of 2 quarters · filed 2024-11-07 | -$90.00M 10-Q · filed 2024-11-07 | $525.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $29.00M 10-Q · filed 2024-11-07 | $111.00M 10-Q · filed 2024-08-08 | $726.00M derived: sum of 3 quarters · filed 2025-02-25 | $368.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $82.00M 10-Q · filed 2024-11-07 | $697.00M derived: sum of 2 quarters · filed 2025-02-25 | $339.00M derived: sum of 3 quarters · filed 2025-02-25 | -$124.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $615.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $257.00M derived: sum of 2 quarters · filed 2025-02-25 | -$206.00M derived: sum of 3 quarters · filed 2025-02-25 | -$183.00M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$358.00M 10-Q · filed 2023-11-07 | -$821.00M derived: sum of 2 quarters · filed 2023-11-07 | -$798.00M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$463.00M 10-Q · filed 2023-11-07 | -$440.00M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $23.00M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | -$512.00M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |